Literature DB >> 12086874

Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.

Andrew Xiao1, Hua Wu, Pier Paolo Pandolfi, David N Louis, Terry Van Dyke.   

Abstract

We have inactivated pRb, p107, and p130 in astrocytes by transgenic expression of T(121) (a truncated SV40 T antigen) under the GFAP promoter. Founder mice died perinatally with extensive expansion of neural precursor and anaplastic astrocyte populations. In astrocytes, aberrant proliferation and extensive apoptosis were induced. Using a conditional allele of T(121), early lethality was circumvented, and adult mice developed high-grade astrocytoma, in which regions of decreased apoptosis expressed activated Akt. Indeed, astrocytoma development was accelerated in a PTEN(+/-), but not p53(+/-), background. These studies establish a highly penetrant preclinical model for astrocytoma based on events observed in the human disease and further provide insight into the role of PTEN mutation in astrocytoma progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086874     DOI: 10.1016/s1535-6108(02)00029-6

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  59 in total

1.  Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice.

Authors:  Alain de Bruin; Lizhao Wu; Harold I Saavedra; Pamela Wilson; Ying Yang; Thomas J Rosol; Michael Weinstein; Michael L Robinson; Gustavo Leone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

2.  Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation.

Authors:  Fumiaki Okahara; Kouichi Itoh; Akira Nakagawara; Makoto Murakami; Yasunori Kanaho; Tomohiko Maehama
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

3.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 4.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 5.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

6.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

8.  A BAC transgenic mouse model to analyze the function of astroglial SPARCL1 (SC1) in the central nervous system.

Authors:  Jill M Weimer; Amelia Stanco; Jr-Gang Cheng; Ana C Vargo; Santhi Voora; E S Anton
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

Review 10.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.